Formulation, characterization, and <i>in vitro</i>/<i>vivo</i> studies of aclacinomycin A-loaded solid lipid nanoparticles

Jia, Yulin; Ji, Jun; Wang, Feng; Shi, Lei; Yu, Jian; Wang, Dong

doi:10.3109/10717544.2014.974001

Cited by 16 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When particle size is between 50 and 200 nm, nanoparticles tend to accumulate in the liver by RES. This indicates that nanoparticles with a diameter of 50–200 nm were caught by the RES, resulting in sustained release [23,43]. PT-NLC and P-PT-NLC tended to accumulate in the liver more than PT, but PT-NLC and P-PT-NLC appeared to be eliminated from the liver over time.…”

Section: Resultsmentioning

confidence: 99%

The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane

Bang

Huh

et al. 2019

Cancers

View full text Add to dashboard Cite

Strategies for the development of anticancer drug delivery systems have undergone a dramatic transformation in the last few decades. Lipid-based drug delivery systems, such as a nanostructured lipid carrier (NLC), are one of the systems emerging to improve the outcomes of tumor treatments. However, NLC can act as an intruder and cause an immune response. To overcome this limitation, biomimicry technology was introduced to decorate the surface of the nanoparticles with various cell membrane proteins. Here, we designed paclitaxel (PT)-loaded nanostructured lipid carrier (PT-NLC) with platelet (PLT) membrane protein because PLT is involved with angiogenesis and interaction of circulating tumor cells. After PLT was isolated from blood using the gravity-gradient method and it was used for coating PT-NLC. Spherical PT-NLC and platelet membrane coated PT-NLC (P-PT-NLC) were successfully fabricated with high encapsulation efficiency (EE) (99.98%) and small particle size (less than 200 nm). The successful coating of PT-NLC with a PLT membrane was confirmed by the identification of CD41 based on transmission electron microscopy (TEM), western blot assay and enzyme-linked immunosorbent assay (ELISA) data. Moreover, the stronger affinity of P-PT-NLC than that of PT-NLC toward tumor cells was observed. In vitro cell study, the PLT coated nanoparticles successfully displayed the anti-tumor effect to SK-OV-3 cells. In summary, the biomimicry carrier system P-PT-NLC has an affinity and targeting ability for tumor cells.

show abstract

Section: Resultsmentioning

confidence: 99%

The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane

Bang

Huh

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…As is well known, the particle size distribution is one of the most important properties used to evaluate the stability of colloidal systems. 35 The mean particle diameter of the optimized NRG-SLNs suspension was determined immediately after production to be 98±0.61 nm with a PDI of 0.258±0.058 ( Figure 2A ). The PDI is an indicator of the homogeneity of the size distribution, and the narrow size distribution and uniform size confirmed the homogeneous nature of the formulation.…”

Section: Resultsmentioning

confidence: 99%

Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics

Ji¹,

Yu²,

Liu³

et al. 2016

DDDT

View full text Add to dashboard Cite

Naringenin (NRG), a flavonoid compound, had been reported to exhibit extensive pharmacological effects, but its water solubility and oral bioavailability are only~46±6 µg/mL and 5.8%, respectively. The purpose of this study is to design and develop NRG-loaded solid lipid nanoparticles (NRG-SLNs) to provide prolonged and sustained drug release, with improved stability, involving nontoxic nanocarriers, and increase the bioavailability by means of pulmonary administration. Initially, a group contribution method was used to screen the best solid lipid matrix for the preparation of SLNs. NRG-SLNs were prepared by an emulsification and low-temperature solidification method and optimized using an orthogonal experiment approach. The morphology was examined by transmission electron microscopy, and the particle size and zeta potential were determined by photon correlation spectroscopy. The total drug content of NRG-SLNs was measured by high-performance liquid chromatography, and the encapsulation efficiency (EE) was determined by Sephadex gel-50 chromatography and high-performance liquid chromatography. The in vitro NRG release studies were carried out using a dialysis bag. The best cryoprotectant to prepare NRG-SLN lyophilized powder for future structural characterization was selected using differential scanning calorimetry, powder X-ray diffraction, and Fourier transform infrared spectroscopy. The short-term stability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, cellular uptake, and pharmacokinetics in rats were studied after pulmonary administration of NRG-SLN lyophilized powder. Glycerol monostearate was selected to prepare SLNs, and the optimal formulation of NRG-SLNs was spherical in shape, with a particle size of 98 nm, a polydispersity index of 0.258, a zeta potential of −31.4 mV, a total drug content of 9.76 mg, an EE of 79.11%, and a cumulative drug release of 80% in 48 hours with a sustained profile. In addition, 5% mannitol (w/v) was screened as a cryoprotectant. Fourier transform infrared spectroscopy, differential scanning calorimetry, and powder X-ray diffraction studies confirmed that the drug was encapsulated into SLNs in an amorphous form. The lyophilized powder was stable at both refrigeration (4°C) and ambient temperature (25°C) for 3 months, and the MTT assay demonstrated that the SLNs were nontoxic. The cellular uptake of fluorescein isothiocyanate-labeled SLNs in A549 cells was highly time dependent over a period of 3 hours, while the pharmacokinetic study in Sprague Dawley rats showed that the relative bioavailability of NRG-SLNs was 2.53-fold greater than that of NRG suspension after pulmonary administration. This study shows that SLNs offer a promising pulmonary delivery system to increase the bioavailability of the poorly water-soluble drug NRG.

show abstract

“…Lipid carriers such as liposomes (Doddapaneni et al, 2016 ), solid lipid nanoparticles (Jia et al, 2016 ), lipid–polymer hybrid nanoparticles (Fang et al, 2010 ), and nanostructured lipid carriers (NLCs) (Alam et al, 2013 ) have been used to encapsulate drugs for the cancer therapy. NLCs, formulated with biocompatible solid and liquid lipids, are an improved generation of SLNs, providing a delivery system for various active drugs with controlled-release characteristic (Song et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer

Yang

Dong

2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles

Cited by 16 publications

References 19 publications

The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane

The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane

Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics

Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer

Contact Info

Product

Resources

About